Boston Pharmaceuticals appoints Board member Dr. Elias Zerhouni as new Chair of Its Board of Directors

– USA, MA –  Boston Pharmaceuticals, a clinical-stage biopharmaceutical company developing differentiated molecules addressing serious liver diseases, appoints current Board member and Scientific Advisor Dr. Elias Zerhouni as the new Chair of its Board of Directors, succeeding Stefan Meister who steps down from the Board.

About Dr. Elias Zerhouni

Dr. Zerhouni in assuming the position of Chair, will now work even more closely with Sophie Kornowski, CEO of Boston Pharmaceuticals, her team, and the community of liver experts as the company’s promising drug candidates accelerate their development.

In particular, over the past few years, Boston Pharmaceuticals has emerged with two exciting candidates in liver diseases and is focused on accelerating BOS-580, the company’s investigational, long-acting, once-monthly fibroblast growth factor 21 analog for the treatment of metabolic dysfunction-associated steatohepatitis.

Dr. Elias Zerhouni said: “I am delighted that Elias has taken on this additional leadership role. His vast experience and expertise will, I am sure, prove invaluable as we navigate the paths of our candidates through clinical development. I also want to thank Stefan for all of his many and sizeable contributions and accomplishments during his time as a colleague. I and the rest of the company are sincerely grateful to him for his role in helping Boston Pharmaceuticals get to this exciting stage in our journey.”

Dr. Zerhouni is a Professor Emeritus in Radiology and Biomedical Engineering at Johns Hopkins University and was most recently the President of Global Research & Development and a member of the Executive Committee for Sanofi. He also served as the Director of the National Institutes of Health from 2002 to 2008. He has been, since 2020, a member of the Board at B-Flexion and is also President and Vice-Chairman of OPKO Health.

About Boston Pharmaceuticals

Boston Pharmaceuticals is a clinical-stage biopharmaceutical company that leverages an experienced and committed drug development team to advance a portfolio of highly differentiated therapies that may address important unmet medical needs in serious liver diseases, with MASH as the focus of its lead asset. The Company has significant expansion opportunities through its portfolio of promising drug development candidates that were acquired through partnerships with proven, innovative biotechnology and pharmaceutical companies. Boston Pharmaceuticals applies rigorous decision-making to advance programs to deliver differentiated medicines to patients in need of new options while creating value for all parties involved in the journey.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.